CO2022006712A2 - Inhibidores de las cinasas raf - Google Patents
Inhibidores de las cinasas rafInfo
- Publication number
- CO2022006712A2 CO2022006712A2 CONC2022/0006712A CO2022006712A CO2022006712A2 CO 2022006712 A2 CO2022006712 A2 CO 2022006712A2 CO 2022006712 A CO2022006712 A CO 2022006712A CO 2022006712 A2 CO2022006712 A2 CO 2022006712A2
- Authority
- CO
- Colombia
- Prior art keywords
- kinase inhibitors
- raf kinase
- compounds
- raf
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962925596P | 2019-10-24 | 2019-10-24 | |
| US202063044898P | 2020-06-26 | 2020-06-26 | |
| PCT/US2020/057132 WO2021081375A1 (en) | 2019-10-24 | 2020-10-23 | Inhibitors of raf kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022006712A2 true CO2022006712A2 (es) | 2022-05-31 |
Family
ID=75619376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0006712A CO2022006712A2 (es) | 2019-10-24 | 2022-05-20 | Inhibidores de las cinasas raf |
Country Status (16)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| AU2020371727B2 (en) * | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| US20230046018A1 (en) * | 2019-12-06 | 2023-02-16 | Medshine Discovery Inc. | Biaryl compound as pan-raf kinase inhibitor |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022060996A1 (en) * | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| JP7825636B2 (ja) * | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) * | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
| US20240327343A1 (en) * | 2021-07-19 | 2024-10-03 | Kinnate Biopharma Inc. | Preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride |
| CN115974851A (zh) * | 2021-10-14 | 2023-04-18 | 华领医药技术(上海)有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023070053A1 (en) * | 2021-10-21 | 2023-04-27 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| AU2022405115A1 (en) * | 2021-12-09 | 2024-07-11 | Deciphera Pharmaceuticals, Llc | Raf kinase inhibitors and methods of use thereof |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| TW202342055A (zh) | 2022-02-03 | 2023-11-01 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| US20250171462A1 (en) * | 2022-03-02 | 2025-05-29 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| US20260100247A1 (en) * | 2022-09-30 | 2026-04-09 | Foundation Medicine, Inc. | Systems and methods for processing clinico-genomic data |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EP2252612B1 (en) | 2008-02-22 | 2012-03-28 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| KR101652229B1 (ko) | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| ES2844211T3 (es) | 2014-09-12 | 2021-07-21 | Novartis Ag | Compuestos y composiciones en calidad de inhibidores de quinasa |
| UY36294A (es) * | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| JP6636014B2 (ja) * | 2014-09-12 | 2020-01-29 | ノバルティス アーゲー | Rafキナーゼ阻害剤としての化合物および組成物 |
| BR112018075371A2 (pt) | 2016-06-10 | 2019-03-19 | Novartis Ag | usos terapêuticos de um inibidor de c-raf |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| JP2022525885A (ja) * | 2019-03-22 | 2022-05-20 | キネート バイオファーマ インク. | Rafキナーゼの阻害剤 |
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
-
2020
- 2020-10-23 AU AU2020371727A patent/AU2020371727B2/en active Active
- 2020-10-23 WO PCT/US2020/057132 patent/WO2021081375A1/en not_active Ceased
- 2020-10-23 CN CN202080090257.4A patent/CN114845711B/zh active Active
- 2020-10-23 IL IL292424A patent/IL292424B2/en unknown
- 2020-10-23 KR KR1020227016515A patent/KR20220104702A/ko active Pending
- 2020-10-23 EP EP20878472.8A patent/EP4048259A4/en active Pending
- 2020-10-23 TW TW109136965A patent/TWI899110B/zh active
- 2020-10-23 CA CA3158530A patent/CA3158530A1/en active Pending
- 2020-10-23 JP JP2022523904A patent/JP7626910B2/ja active Active
- 2020-10-23 PH PH1/2022/550976A patent/PH12022550976A1/en unknown
- 2020-10-23 US US17/079,152 patent/US11098031B1/en active Active
- 2020-10-23 MX MX2022004937A patent/MX2022004937A/es unknown
- 2020-10-23 BR BR112022007612A patent/BR112022007612A2/pt unknown
-
2021
- 2021-03-25 US US17/213,036 patent/US12312336B2/en active Active
-
2022
- 2022-04-14 ZA ZA2022/04284A patent/ZA202204284B/en unknown
- 2022-04-21 CL CL2022000998A patent/CL2022000998A1/es unknown
- 2022-05-20 CO CONC2022/0006712A patent/CO2022006712A2/es unknown
-
2025
- 2025-04-18 US US19/183,462 patent/US20260055084A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022004937A (es) | 2022-07-27 |
| US11098031B1 (en) | 2021-08-24 |
| EP4048259A1 (en) | 2022-08-31 |
| EP4048259A4 (en) | 2023-08-02 |
| AU2020371727B2 (en) | 2026-01-22 |
| JP7626910B2 (ja) | 2025-02-05 |
| US20260055084A1 (en) | 2026-02-26 |
| TW202128680A (zh) | 2021-08-01 |
| CA3158530A1 (en) | 2021-04-29 |
| BR112022007612A2 (pt) | 2022-09-20 |
| PH12022550976A1 (en) | 2023-09-25 |
| IL292424B2 (en) | 2026-06-01 |
| NZ788005A (en) | 2024-10-25 |
| IL292424B1 (en) | 2026-02-01 |
| CN114845711A (zh) | 2022-08-02 |
| KR20220104702A (ko) | 2022-07-26 |
| TWI899110B (zh) | 2025-10-01 |
| IL292424A (en) | 2022-06-01 |
| JP2022554169A (ja) | 2022-12-28 |
| CL2022000998A1 (es) | 2023-02-10 |
| ZA202204284B (en) | 2024-09-25 |
| US12312336B2 (en) | 2025-05-27 |
| WO2021081375A1 (en) | 2021-04-29 |
| AU2020371727A1 (en) | 2022-05-26 |
| US20210300904A1 (en) | 2021-09-30 |
| CN114845711B (zh) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2021008224A2 (es) | Inhibidores de kif18a | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2020001931A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| MX2022008740A (es) | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CO2022010330A2 (es) | Dosificación de gamma-hidroxibutirato (ghb) | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| CO2018010504A2 (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
| CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| CO2017011484A2 (es) | Inhibidores de bromodominio | |
| CL2025000629A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| MX384213B (es) | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| CO2022018806A2 (es) | Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| CO2024009144A2 (es) | Inhibidores de cinasa met |